India's first indigenous COVID-19 vaccine Covaxin is effective against the Delta Plus variant of coronavirus, according to a study conducted by Indian Council of Medical Research (ICMR), news agency ANI reported.

Covaxin has been developed by Bharat Biotech, in collaboration with ICMR.

Bharat Biotech in July had said that it has submitted all documents to the World Health Organisation (WHO) for Emergency Use Listing (EUL) of Covaxin and the review process has begun.

The Hyderabad-based company had said in May that that application for EUL was submitted to WHO-Geneva and regulatory approvals are expected by July-September 2021.

On June 30, the vaccine maker announced that it is working closely with the WHO for inclusion of Covaxin in its EUL.

"Approval from WHO is not expected to be a long-drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," it had said.